Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1891 3
1892 1
1893 2
1896 2
1901 1
1902 1
1903 1
1906 1
1907 1
1910 1
1929 1
1930 3
1932 1
1935 1
1939 1
1945 2
1946 3
1947 1
1951 1
1952 1
1953 2
1954 2
1957 1
1959 1
1960 1
1962 3
1965 2
1967 3
1970 1
1971 2
1972 3
1973 2
1974 3
1977 4
1978 3
1980 1
1981 1
1983 2
1984 1
1987 1
1988 3
1991 2
1993 1
1998 1
2002 3
2003 2
2005 3
2006 2
2007 3
2008 11
2009 18
2010 27
2011 23
2012 24
2013 24
2014 16
2015 30
2016 35
2017 28
2018 26
2019 30
2020 46
2021 31
2022 30
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

422 results
Results by year
Filters applied: . Clear all
Page 1
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response.
Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI. Biasci D, et al. Among authors: basu b. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960-28970. doi: 10.1073/pnas.2013644117. Epub 2020 Oct 30. Proc Natl Acad Sci U S A. 2020. PMID: 33127761 Free PMC article.
Characterizing the morbid genome of ciliopathies.
Shaheen R, Szymanska K, Basu B, Patel N, Ewida N, Faqeih E, Al Hashem A, Derar N, Alsharif H, Aldahmesh MA, Alazami AM, Hashem M, Ibrahim N, Abdulwahab FM, Sonbul R, Alkuraya H, Alnemer M, Al Tala S, Al-Husain M, Morsy H, Seidahmed MZ, Meriki N, Al-Owain M, AlShahwan S, Tabarki B, Salih MA; Ciliopathy WorkingGroup, Faquih T, El-Kalioby M, Ueffing M, Boldt K, Logan CV, Parry DA, Al Tassan N, Monies D, Megarbane A, Abouelhoda M, Halees A, Johnson CA, Alkuraya FS. Shaheen R, et al. Among authors: basu b. Genome Biol. 2016 Nov 28;17(1):242. doi: 10.1186/s13059-016-1099-5. Genome Biol. 2016. PMID: 27894351 Free PMC article.
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren MH, Kossenkov A, Sanseviero E, Raulf N, Vasara J, Andrikakou P, Meyer T, Huang KW, Plummer R, Chee CE, Spalding D, Pai M, Khan S, Pinato DJ, Sharma R, Basu B, Palmer D, Ma YT, Evans J, Habib R, Martirosyan A, Elasri N, Reynaud A, Rossi JJ, Cobbold M, Habib NA, Gabrilovich DI. Hashimoto A, et al. Among authors: basu b. Clin Cancer Res. 2021 Nov 1;27(21):5961-5978. doi: 10.1158/1078-0432.CCR-21-0986. Epub 2021 Aug 18. Clin Cancer Res. 2021. PMID: 34407972 Free PMC article. Clinical Trial.
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer.
Kocher HM, Basu B, Froeling FEM, Sarker D, Slater S, Carlin D, deSouza NM, De Paepe KN, Goulart MR, Hughes C, Imrali A, Roberts R, Pawula M, Houghton R, Lawrence C, Yogeswaran Y, Mousa K, Coetzee C, Sasieni P, Prendergast A, Propper DJ. Kocher HM, et al. Among authors: basu b. Nat Commun. 2020 Sep 24;11(1):4841. doi: 10.1038/s41467-020-18636-w. Nat Commun. 2020. PMID: 32973176 Free PMC article. Clinical Trial.
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Guo C, Chénard-Poirier M, Roda D, de Miguel M, Harris SJ, Candilejo IM, Sriskandarajah P, Xu W, Scaranti M, Constantinidou A, King J, Parmar M, Turner AJ, Carreira S, Riisnaes R, Finneran L, Hall E, Ishikawa Y, Nakai K, Tunariu N, Basu B, Kaiser M, Lopez JS, Minchom A, de Bono JS, Banerji U. Guo C, et al. Among authors: basu b. Lancet Oncol. 2020 Nov;21(11):1478-1488. doi: 10.1016/S1470-2045(20)30464-2. Epub 2020 Oct 28. Lancet Oncol. 2020. PMID: 33128873 Clinical Trial.
Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K. Chan EY, et al. Among authors: basu b. J Am Soc Nephrol. 2022 Jun;33(6):1193-1207. doi: 10.1681/ASN.2021111472. Epub 2022 Mar 30. J Am Soc Nephrol. 2022. PMID: 35354600
Caudamins, a new subclass of protein hormones.
Basu B, Jain M, Chopra AR. Basu B, et al. Trends Endocrinol Metab. 2021 Dec;32(12):1007-1014. doi: 10.1016/j.tem.2021.09.005. Epub 2021 Oct 16. Trends Endocrinol Metab. 2021. PMID: 34666940 Review.
422 results